Clinical Study

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients

Table 1

Characteristics of patients.

Total ( )%

Age (years)
 Median (range)79 (62–93)
 Age >705489
Performance status
 Karnofsky index ≤70%3252
Histology
 Invasive ductal5285
 Invasive lobular915
Clinical stage
 I23
 II2236
 III2744
 IV1017
 T4 tumors3354
 N+4879
Primary treatment
 Hormonal therapy61100
  Tamoxifen only5489
  Tamoxifen switched to Al*711
 Radiation therapy1525
 Surgery12
Initial response to primary treatment
 Responders**4879
  Complete response (CR)610
  Partial response (PR)3964
  Stable disease (SD)35
 Nonresponders***1321
  Progressive disease (PD)915
  Stable disease (SD)46

Annotations. Switch of the tamoxifen to an aromatase inhibitor was carried out due to tamoxifen's side effects (mostly endometrial hyperplasia). All seven patients achieved partial remission in the course of tamoxifen therapy.
Patients who achieved complete or partial (reduction of disease by 30% or more) remission or had long-lasting disease stabilization (stable disease for at least 33 months; median of PFS).
Patients who never responded to primary treatment or achieved stable disease for less than 12 months during the period of primary treatment.